Critics Call FDA Third-Party Social Media Guidance ‘Overbroad’
This article was originally published in The Gray Sheet
Executive Summary
Some stakeholders are concerned the agency’s draft guidance is overreaching and could have a chilling effect. AdvaMed recommends FDA consider splitting the guidance into product-specific documents to reference regulations that may apply to industries differently.